The malignant melanoma market in Europe has become crowded. Small-molecule targeted therapies such as Novartis’s Tafinlar and Mekinist, monoclonal antibodies including Merck & Co.’s Keytruda and Bristol-Myers Squibb’s Opdivo, and Amgen’s therapeutic vaccine Imygic have all been approved in the last six years. The premium price of these agents has resulted in spiraling healthcare costs, which means payers must make increasingly economical reimbursement decisions. In turn, oncologists face mounting challenges as they strive to balance superior efficacy and clinical need with strict eligibility criteria and other prescribing restrictions set by healthcare agencies. This research examines the reimbursement environment for malignant melanoma in the EU5, and analyzes the evolving impact of payer policy on prescribing as additional costly therapies penetrate the market and healthcare budgets tighten.
Access & Reimbursement: Provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.